Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls by Maetzler, Walter et al.
Comparable Autoantibody Serum Levels against
Amyloid- and Inflammation-Associated Proteins in
Parkinson’s Disease Patients and Controls
Walter Maetzler1,2*., Anja Apel1,2., Markus Langkamp3., Christian Deuschle1,2, Sarah Selina Dilger1,2,
Johannes Georg Stirnkorb1,2, Claudia Schulte1,2, Erwin Schleicher4, Thomas Gasser1,2, Daniela Berg1,2
1Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany, 2DZNE, German
Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany, 3Mediagnost, Reutlingen, Germany, 4Department of Internal Medicine IV,
University Hospital Tuebingen, Tuebingen, Germany
Abstract
Naturally occurring autoantibodies (NAbs) against a number of potentially disease-associated cellular proteins, including
Amyloid-beta1–42 (Abeta1–42), Alpha-synuclein (Asyn), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein
(MOG), and S100 calcium binding protein B (S100B) have been suggested to be associated with neurodegenerative
disorders, in particular Alzheimer’s (AD) and Parkinson’s disease (PD). Whereas the (reduced) occurrence of specific NAbs in
AD is widely accepted, previous literature examining the relation of these NAb titres between PD patients and controls, as
well as comparing these levels with demographic and clinical parameters in PD patients have produced inconsistent
findings. We therefore aimed, in a cross-sectional approach, to determine serum titres of the above NAbs in a cohort of 93
PD patients (31 of them demented) and 194 controls. Levels were correlated with demographic and clinical variables,
cerebrospinal fluid Abeta1–42, total tau and phospho-tau levels, as well as with single nucleotide polymorphisms (SNPs) of
genes which either have been reported to influence the immune system, the amyloid cascade or the occurrence of PD
(ApoE, GSK3B, HLA-DRA, HSPA5, SNCA, and STK39). The investigated NAb titres were neither significantly associated with the
occurrence of PD, nor with demographic and clinical parameters, neurodegenerative markers or genetic variables. These
results argue against a major potential of blood-borne parameters of the adaptive immune system to serve as trait or state
markers in PD.
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Introduction
Naturally occurring autoantibodies (NAbs) probably act in
eliminating circulating proteins, before they can elicit a damaging
response [1,2]. In the context of neurodegenerative disorders
evidence has accumulated that such NAbs also exist which may be
involved e.g. in the physiologic clearance of the misfolded proteins
[1,3]. More specifically, evidence accumulates that individuals
with increased risk for, and patients with Alzheimer’s disease (AD)
have altered levels of NAbs that are directed against Amyloid-beta
(Abeta) [4–7]. This has recently led to a phase 2 clinical trial with
intravenous immunoglobulin in AD patients [8]. The role of NAbs
in idiopathic Parkinson’s disease (PD) is less clear. Blood-borne
NAbs directed against the putatively most important self-antigen
in PD, Alpha-synuclein (Asyn), have been reported to be higher
[9,10], not significantly different [11] and lower [12] compared to
respective control cohorts. All the above-mentioned studies used
recombinant Asyn as an antigen.
In a previous work, we found higher serum NAb levels against
recombinant Abeta1–42, Asyn, myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG), and S100 calcium binding
protein B (S100B) in 13 demented PD patients as well as in 14
patients with dementia with Lewy bodies (DLB), compared to 33
patients with other dementias and 31 controls [13]. An increased
immune response to S100B in PD was also found in another study
[14], supporting the view that S100B may be crucially involved in
the pathophysiology of PD [15]. Also, higher Asyn NAb levels
were very recently found in 19 DLB patients (and in 15 AD
patients) compared to 16 control individuals [16]. The role of the
above mentioned proteins is well established, but the influence of
the corresponding NAbs is not well defined.
As all of the mentioned studies included relatively small cohort
sizes, here we tested the utility of serum levels of the above
mentioned NAbs as potential markers of presence and severity
(including cognitive dysfunction) of PD in a considerably larger
cohort of PD patients and controls, using a comprehensive test
battery including demographic, clinical and neurodegenerative
parameters. Moreover, we evaluated respective NAb titres in
association with different single nucleotide polymorphisms (SNPs)
of genes which either have been reported to influence the activity
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of the adaptive immune system, the amyloid cascade or have been
associated with the occurrence of PD (APOE [17,18], GSK3B
[19,20], HLA-DRA [21,22], HSPA5 [23,24], SNCA [25–27], and
STK39 [28,29]).
Materials and Methods
Ethics Statement
The study was approved by the local ethics committee (Ethics
committee of the medical faculty of Eberhard Karls University
Tuebingen and of the University Hospital Tuebingen, Tuebingen,
Germany), and was performed according to the principles
expressed in the Declaration of Helsinki. All participants capable
to consent gave their written informed consent. In case of
compromised capacity of the participants to consent (MMSE #18
points, and/or another person was named to make decisions on
behalf of the person), responsible persons gave their written
consent on the behalf of the participant.
Study Participants
Ninety three PD patients were recruited from the ward and the
outpatient clinic of the Neurodegenerative Department of the
University of Tuebingen. They were diagnosed by specialists in the
field of neurodegenerative movement disorders (WM, TG, DB),
and fulfilled the UKPDS Brain Bank criteria [30]. Demented PD
(PDD) patients also met dementia criteria of the Diagnostic and
Statistical Manual of Mental Disorders-IV (DSM-IV). One
hundred and ninety-four healthy controls were recruited from
the TREND study (www.trend-studie.de) [31,32]. Any clinical sign
for a neurodegenerative disorder in these individuals led to
exclusion from the study. Individuals with recent medical history
or actual clinical and laboratory signs for inflammation or
infection were not included.
Medical history and demographics were obtained from all
individuals (sex, age, age at onset parkinsonism and dementia), and
all participants underwent clinical testing including a Hoehn &
Yahr (H&Y) staging and a Mini-Mental State Examination
(MMSE).
Table 1 and Table 2 provide an overview of demographic,
clinical, and biochemical data of the cohorts and subcohorts.
Cerebrospinal Fluid and Serum Collection
Serum collection was performed according to standardized
protocols, for details see [33]. In brief, blood was centrifuged
(2000 g, 4uC, 10 min) and stored at 280uC within 60 minutes
after collection until analysis. Of patients who also underwent
lumbar puncture, only those with normal routine CSF diagnostics
were included (n= 36); slightly increased CSF albumin levels (up
to 450 mg/L) were tolerated. CSF was also centrifuged (4000 g,
4uC, 10 min) and stored at 280uC within 60 min after collection.
Spinal taps were only performed in patients but not in controls due
to the invasive nature of CSF sampling.
NAb ELISAs
The detailed process of ELISA development and measurement
procedures has been described previously [13,34]. In brief, for
quantitative determination of NAbs against Abeta1–42, Asyn,
MBP, MOG, S100B, and scrambled Abeta1–40 (for assessment of
unspecific binding) high binding microtiter plates were coated with
commercially available recombinant proteins expressed in E. coli
(non-modified Abeta1–42, non-modified Asyn, and scrambled
Abeta1–40 with the amino acid sequence KVKGLIDGAHIGDL-
VYEFMASNSFREGVGAGHVHVAQVEF, all from rPeptide,
Bogart, Georgia GA, USA) or purified native protein (human
S100B, Cell Sciences, Canton, Massachusetts MA, USA; bovine
MBP and MOG, GMBU eV, Halle, Germany). Optimal
concentration for protein immobilization was determined for each
protein individually. Thus, 100 ml of a 5 mg/L Abeta1–42, 1 mg/L
Asyn, 10 mg/L MBP, 10 mg/L MOG, and 1 mg/L S100B
solution, respectively, were incubated in a well of a high binding
microtiter plate (Corning Inc, Lowell, Massachusetts MA, USA)
overnight at room temperature. For control purposes [35]
microtiter plates were coated with 1 mg/L scrambled Abeta1–40
[36]. Non-specific binding was blocked by an ensuing incubation
with 1% BSA in phosphate buffered saline with a pH of 7.4. After
washing and drying, plates were incubated with diluted human
serum samples under agitation at 350 rpm for 2 h at room
temperature. The biotinylated detection antibody and horserad-
ish-peroxidase streptavidin-conjugate were then added sequential-
ly. Each was incubated for 60 min at room temperature. After the
addition of substrate and stop solution, optical densities of the
reactions were measured at 450 nm. For specificity reasons each
sample was also applied to uncoated wells and the resulting
unspecific signal was subtracted from the signal of the wells coated
with the antigen. In addition, all respective scrambled Abeta1–40
NAb titres were subtracted from individual NAb titres. For
quantification, an internal serum standard was applied and
arbitrary titre units were calculated. All samples were measured
within the same test kit lot. Inter-assay variability within this study
was measured by applying four control samples and revealed a
Table 1. Demographic, clinical, routine biochemical and
genetic data of the cohorts.
PD Controls p-values
Individuals (f in %) 93 (38.7) 194 (55.7) 0.007*
Age (years) 70 (44–88) 63 (50–80) ,0.0001*
AAO parkinsonism (years) 62 (39–84)
Duration parkinsonism (years) 9.5 (1–26)
H&Y stage (1–5) 2 (1–4)
BDI (0–63) 9 (1–29) 5.5 (0–40) 0.0007*
MMSE (0–30) 27 (10–30) 29 (27–30) ,0.0001*
UPDRS (0–199) 5 (0–43) 0 (0–7) ,0.0001*
CSF Abeta1–42 (pg/ml) 540 (141–1127)
CSF t-tau (pg/ml) 217 (61–927)
CSF p-tau (pg/ml) 43 (21–107)
ApoE4 (%) 19.35 25.77 0.23
GSK3B (A allele of SNP
rs6438552)
86.36 82.47 0.65
HLA-DRA (A allele of SNP
rs3129882)
82.05 73.58 0.14
HSPA5 (A allele of SNP rs430397) 12.86 15.03 0.66
SNCA (G allele of SNP rs356219) 56.41 65.46 0.16
STK39 (A allele of SNP rs4668049) 31.08 25.4 0.35
Demographic, clinical and biochemical data of patients with Parkinson’s disease
(PD) and controls are presented with median (range) or percentage of total. P-
values were determined using the Wilcoxon rank sum test or the Fisher’s exact
test. Aao, age at onset; ApoE4, at least one Apolipoprotein E4 allele; BDI, Beck
Depression Inventory; CSF, cerebrospinal fluid; f, female; GSK3B, Glycogen
synthase kinase 3 beta; HLA-DRA, Human leucocyte antigen/Major
histocompatibility complex, class II, DR alpha chain; HSPA5, Heat shock 70 kDa
protein 5; H&Y, Hoehn & Yahr stage; MMSE, Mini-Mental State Examination; p-
tau, phospho-tau; SNCA, Synuclein alpha; STK39, Serine threonine kinase 39; t-tau,
total tau; UPDRS, Unified Parkinson’s Disease Rating Scale.
doi:10.1371/journal.pone.0088604.t001
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variation of 9; 12; 13; 10; 12 and 15% for Abeta1–42, Asyn, MBP,
MOG, S100B, and scrambled Abeta1–40, respectively. The
analytical sensitivities, defined as the mean NAb titre of the zero
sample +3 SD, were 0.52; 0.35; 0.48; 0.30; 0.83 arbitrary titre
units for Abeta1–42, Asyn, MBP, MOG, and S100B specific NAbs
(n $12), respectively.
All NAb ELISA measurements were performed at Mediagnost,
Reutlingen, Germany, blinded to clinical and demographic data.
Abeta1–42, Total Tau and Phospho-tau Measurement
CSF Abeta1–42, total tau and phospho-tau levels were deter-
mined using commercially available ELISA kits (Innogenetics NV,
Ghent, Belgium). We did not determine Asyn levels because we
did not have access to CSF of controls, and the value of Asyn levels
in blood for the differentiation of PD from controls is very
probably low [12].
SNP and ApoE Genotyping
Genomic DNA was extracted using standard protocols. SNPs
located at the exon (rs429358 and rs7412 in exon 4 of the APOE
gene), the intron (rs6438552 of GSK3B, rs3129882 of HLA-DRA,
rs430397 of HSPA5, rs4668049 of STK39) or the untranslated
region (rs356219 in the 39-UTR of SNCA) were analyzed by the
SNaPshot method. Briefly, a PCR with specific SNaPshot primers
was performed. After single base extension with fluorescent-
labelled ddNTPs the SNaPshot product was analyzed by capillary
gel electrophoresis with ABI Prism 3100 Genetic Analyzer
sequencer (Applied Biosystems Life Technologies GmbH, Darm-
stadt, Germany). Fluorescence data were analyzed using Gene
MapperTM Software v3.5, Applied Biosystems, Foster City,
California CA, USA). All SNPs investigated were in Hardy-
Weinberg equilibrium.
Data Analysis
Data were analyzed with JMP software (version 9.0.2, SAS
Institute Inc., Cary, North Carolina NC, USA). Demographic and
clinical data are generally presented with the median and range
(continuous data), or percentage of total (dichotomous data). P-
values were obtained with the Wilcoxon rank sum or the Fisher’s
exact test (PD versus controls; PD non-demented (PDND) versus
PDD). NAb titres were logarithmized due to non-normal
distribution. Associations of NAb titres with demographic, clinical
or neurochemical data were calculated using multiple linear
regression models, with age and gender (PD versus controls), and
age, gender, age at onset and disease duration (PDND vs. PDD) as
covariates. Differences were considered significant at p,0.05.
Post-hoc analyses were corrected for multiple testing (i.e. 0.05
divided by the number of groups, see Table S1, S2, S3).
Results
Serum NAb Titres and Demographic Variables
Serum NAb titres of controls were not age-related (Abeta1–42,
r2 = 0.00, p=0.96; Asyn, r2 = 0.00, p=0.74; MBP, r2 = 0.00,
p=0.76; MOG, r2 = 0.01, p=0.16; S100B, r2 = 0.00, p=0.53)
and were comparable between females and males (0.19,p,0.92).
Serum NAb Titres in Association with Diagnosis and
Disease-associated Parameters
An overview of the association between NAbs and diagnosis is
given in Table 3 and Table 4. Serum NAb titres differed neither
significantly between PD patients and controls, nor between
PDND and PDD patients. None of the NAb titres correlated
significantly with demographic or clinical parameters (age at onset
Table 2. Demographic, clinical, routine biochemical and
genetic data of the subcohorts.
PDND PDD p-values
Individuals (f in %) 62 (40.3) 31 (35.5) 0.65
Age (years) 68 (44–84) 74 (54–88) ,0.0001*
AAO parkinsonism (years) 60 (39–78) 64 (48–84) 0.008*
Duration parkinsonism (years) 7 (1–23) 11 (1–26) 0.11
Aao dementia (years) 69 (50–80)
Duration dementia (years) 5 (0–10)
H&Y stage (1–5) 2 (1–3.5) 2.25 (1–4) 0.24
BDI (0–63) 8.5 (1–21) 9 (2–29) 0.77
MMSE (0–30) 28.5 (19–30) 23 (10–26) ,0.0001*
UPDRS (0–199) 7 (0–37) 3 (0–43) 0.60
CSF Abeta1–42 (pg/ml) 750 (269–1127) 419 (141–737) ,0.0001*
CSF t-tau (pg/ml) 195 (109–432) 244 (61–927) 0.18
CSF p-tau (pg/ml) 43 (26–72) 42 (21–107) 0.69
ApoE4 (%) 22.58 12.9 0.27
GSK3B (A allele of SNP
rs6438552)
92.86 75.0 0.24
HLA-DRA (A allele of SNP
rs3129882)
83.33 79.17 0.66
HSPA5 (A allele of SNP rs430397) 11.11 18.75 0.42
SNCA (G allele of SNP rs356219) 58.49 52.0 0.59
STK39 (A allele of SNP rs4668049) 27.45 39.13 0.32
Demographic, clinical and biochemical data of patients with Parkinson’s disease
non-demented (PDND) and Parkinson’s disease with dementia (PDD) are
presented with median (range) or percentage of total. P-values were
determined using the Wilcoxon rank sum test or the Fisher’s exact test. Aao, age
at onset; ApoE4, at least one Apolipoprotein E4 allele; BDI, Beck Depression
Inventory; CSF, cerebrospinal fluid; f, female; GSK3B, Glycogen synthase kinase 3
beta; HLA-DRA, Human leucocyte antigen/Major histocompatibility complex, class
II, DR alpha chain; HSPA5, Heat shock 70 kDa protein 5; H&Y, Hoehn & Yahr stage;
MMSE, Mini-Mental State Examination; p-tau, phospho-tau; SNCA, Synuclein
alpha; STK39, Serine threonine kinase 39; t-tau, total tau; UPDRS, Unified
Parkinson’s Disease Rating Scale.
doi:10.1371/journal.pone.0088604.t002
Table 3. Association of serum NAb titres with diagnosis (PD
patients versus Controls).
Part A
PD Controls p-value
Abeta1–42 NAb (OD) 8.43 (0–11) 8.58 (0–10.98) 0.75
Asyn NAb 6.73 (0–9.46) 6.46 (0–10.80) 0.50
MBP NAb 7.76 (0–10.29) 7.94 (0–10.72) 0.98
MOG NAb 0 (0–8.86) 0 (0–9.51) 0.25
S100B NAb 8.01 (0–11.08) 8.11 (0–11.40) 0.46
Logarithmized serum NAb titres were calculated using a multiple linear
regression model with age, gender (PD versus controls) as covariates. Data are
presented with median (range). P-values ,0.025 (0.05/2) were considered
significant. Abeta1–42, Amyloid-beta1–42; Asyn, Alpha-synuclein; MBP, Myelin
basic protein; MOG, Myelin oligodendrocyte glycoprotein; NAb, naturally
occurring autoantibody; OD, Optical density; PD, Parkinson’s disease; S100B,
S100 calcium binding protein B.
doi:10.1371/journal.pone.0088604.t003
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of parkinsonism, duration of parkinsonism, Hoehn & Yahr stage,
BDI, and MMSE score; see also Table S1).
Serum NAb Titres and Neurodegenerative Markers
No significant correlation between the serum NAb titres, and
CSF Abeta1–42, total tau and p-tau was observed (Table S2).
Serum NAb Titres and SNPs
Table S3 gives an overview of the associations between the NAb
titres and SNPs assessed in this study (APOE, GSK3B, HLA-DRA,
HSPA5, SNCA, and STK39). We did not find a relevant interaction
between these variables.
Discussion
This study indicates that neurodegeneration- and neuroinflam-
mation-associated serum NAbs as used in this large cross-sectional
clinical trial are not useful as trait and state markers in PD. They
also do not seem to be determined by genetic variants associated
with neurodegeneration and neuroinflammation in PD, and are
not significantly associated with neurodegenerative markers in the
CSF.
Our results are, in particular with regard to Asyn NAbs, partly
confirmed by others [10,11] but there are also studies reporting
higher [9,10] and lower [12] Asyn NAb levels in the blood of PD
patients compared to that of controls. Papachroni et al. [11]
examined serum of different kinds of Parkinsonism by immunoblot
detection with denaturated recombinant human alpha-, beta- and
gamma-synucleins. They found that multiepitopic autoantibodies
against Asyn (this term corresponds to ‘‘naturally occurring
autoantibodies’’ as used in this manuscript) are detectable in
65% of all patients tested and their presence strongly correlated
with an inherited mode of PD but not with other disease-related
factors. In more detail, the frequency of autoantibodies was
comparable between patients with the sporadic form of PD and
controls but was clearly increased in patients with familial form of
the disease [11]. Both study cohort (e.g., mean age at examination
65 vs. 70 years, age at onset 60 vs. 62 years, H&Y stage 2.5 vs. 2)
and results (no significant differences between idiopathic PD and
controls) are basically comparable with the results of this study.
Gruden et al. [10] found elevated titres of NAbs against Asyn
monomers, oligomers and fibrils in 72%, 56%, and 17% in the
serum of PD patients, which reached a maximum approximately 5
years after diagnosis and were markedly lower 10 years after
diagnosis. The control cohort showed autoantibody titres against
Asyn, dopamine and S100B which were comparable with levels of
PD patients with a mean disease duration of 10 years. As our study
cohort has a mean disease duration of 9.5 years, our results
basically confirm this result of Gruden and colleagues. Moreover,
as we have a cross-sectional design in this study, we cannot exclude
that patients with PD, as shown in this previous study, have
increased values of respective NAbs at earlier disease stages.
Yanamandra et al. [9] found significantly higher autoantibody
levels towards monomeric Asyn in the serum of patients with PD
with a mean disease duration of 7.7 years, compared to controls
using ELISA and Western Blot. Interestingly, also in this study PD
patients with longer disease duration (9.9 years) had a lower
immune response than those with shorter disease duration (5.9
years, groups divided by use of the H&Y scale). The weakness of
this study is the low sample size however the (repeated) observation
that levels of respective autoantibodies may be particularly high at
early disease stages requires further investigation. Notably, we did
not find any relevant correlation between respective autoantibody
titres and disease duration in our PD cohort.
In the analyses of Besong-Agbo et al. [12] levels of NAbs against
Asyn were significantly lower in patients with PD compared to
healthy controls and patients with AD. Comparable to our study
cohort, their study included patients with rather advanced stages
of PD (mean disease duration 10.2 years, 80% with a H&Y stage
$2). Study cohorts are obviously comparable to our actual study,
thus differences observed between the two studies are not well
explained by demographic and clinical differences of the cohorts.
We also used comparable techniques to consider technical issues
(e.g. background staining, unspecific binding). Thus, differences
are most probably due to the inclusion of different PD phenotypes,
indicating that future research should particularly focus on the
definition of potentially existing endophenotypes of PD which may
be influenced by immune responses. Interestingly, Besong-Agbo
et al. did not detect any relevant association of autoantibody levels
with demographic and clinical variables, including disease
duration, which is comparable to results obtained in this study.
However, here we could not replicate a pilot study performed by
our group, in which we found higher NAb titres, including NAb
titres against Asyn, in a small sample of PDD and DLB patients
(no overlap with the cohort reported here), than in other
dementias and in controls [13].
In addition to the lack of differences between NAb titres of
individuals with or without PD, NAb titres in this study were
neither relevantly associated with disease-associated clinical
parameters (such as H&Y stage and dementia), nor neurochemical
markers or SNPs which were shown to influence the inflammation
or amyloid cascade. At this point it is difficult to explain these
discrepancies between our actual study and previous investiga-
tions, however we consider the following aspects: (i) This is the by
far largest PD cohort studied up to now on this topic, including
patients from the early to very advanced stages (Hoehn & Yahr 1–
4), and with a specific focus on PD patients with cognitive deficits.
As we did not find any relevant associations of NAbs with disease
occurrence and additional disease-associated parameters in this
study, it is most probable that this cohort reflects the general
situation of PD better, than did the pilot study. (ii) This
discrepancy as well as differing results from the previously
mentioned studies may however also indicate that subcohorts -
or endophenotypes - among the Lewy body disorders spectrum
exist which have indeed a (pathophysiologically) relevant change
in NAb levels. (iii) It was hypothesized that the low avidity of the
multiepitopic NAbs can lead to problems in differentiating the
Table 4. Association of serum NAb titres with diagnosis
(PDND patients versus PDD patients).
PDND PDD p-value
Abeta1–42 NAb (OD) 8.54 (0–10.6) 8.23 (0–11) 0.14
Asyn NAb 7.17 (0–9.46) 6.0 (0–9.06) 0.33
MBP NAb 7.90 (0–9.87) 7.64 (0–10.29) 0.03
MOG NAb 0 (0–8.86) 0 (0–8.64) 0.72
S100B NAb 7.92 (0–11.08) 8.10 (5.95–9.52) 0.04
Logarithmized serum NAb titres were calculated using a multiple linear
regression model with age, gender, age at onset parkinsonism and disease
duration parkinsonism as covariates. Data are presented with median (range).
P-values,0.025 (0.05/2) were considered significant. Abeta1–42, Amyloid-beta1–42;
Asyn, Alpha-synuclein; MBP, Myelin basic protein; MOG, Myelin
oligodendrocyte glycoprotein; NAb, naturally occurring autoantibody; OD,
Optical density; PDD, Parkinson’s disease with dementia; PDND, Parkinson’s
disease non-demented; S100B, S100 calcium binding protein B.
doi:10.1371/journal.pone.0088604.t004
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antibody binding signal from unspecific background activity
[12,37]. We addressed this issue by using a specific, biotinylated
goat-anti-human-IgG binding system in combination with a
streptavidin-peroxidase conjugate. Moreover, all results were
corrected for unspecific binding with regard to both, coated
minus uncoated well and specific minus unspecific (individual
NAbs minus scrambled Abeta1–40) detection antibodies.
In this study, we did not differentiate between free and loaded
autoantibody titres. It is indeed probable that, in a physiological
environment, the majority of NAbs are bound to self-antigens [38]
and are thus not or hardly detectable by current assessment
strategies [39]. Future studies should address this aspect however it
may be difficult to measure total amount of respective antibodies
as they can change their binding characteristics under conditions
which lead to release of the antigen-antibody complex [37].
In conclusion, it must be considered that recombinant as well as
purified metabolites may not be ideal for delineating NAb titres in
physiological biofluids, and that the use of altered proteins and
peptides as antigens may have more potential to detect disease-
specific changes of autoantibody levels [40].
Conclusion
These results argue against a relevant potential of serum NAb
titres to serve as trait or state markers in PD.
Supporting Information
Table S1 Association of serum NAb titres with demo-
graphic and clinical parameters. P-values of NAb titres were
calculated using a multiple linear regression model, corrected for
age at onset of parkinsonism, disease duration of parkinsonism,
Hoehn & Yahr stage, age at onset of dementia, and MMSE. P-
values ,0.01 (0.05/5) were considered significant. Abeta1–42,
Amyloid-beta1–42; Asyn, Alpha-synuclein; H&Y, Hoehn & Yahr
stage; MBP, Myelin basic protein; MMSE, Mini-Mental State
Examination; MOG, Myelin oligodendrocyte glycoprotein; NAb,
naturally occuring autoantibody; PD, Parkinson’s disease; S100B,
S100 calcium binding protein B.
(DOC)
Table S2 Association of serum NAb titres with neuro-
degenerative markers. Neurodegenerative markers (CSF
Abeta1–42, t-tau and p-tau) are analyzed as described. NAb titres
of scrambled Abeta1–40 were subtracted from other NAb titres,
and were logarithmized afterwards. P-values of NAb titres were
calculated using the Spearmans non-parametric correlation. Post-
hoc analyses were performed for comparison of NAb titres and
neurodegenerative marker levels between the following cohorts:
PD patients versus controls, Parkinson’s disease non-demented
(PDND) versus Parkinson’s disease with dementia (PDD). P-values
,0.0025 (0.05/20) were considered significant. Abeta1–42, Amy-
loid-beta1–42; Asyn, Alpha-synuclein; CSF, cerebrospinal fluid;
MBP, Myelin basic protein; MOG, Myelin oligodendrocyte
glycoprotein; NAb, naturally occuring autoantibody; PD, Parkin-
son’s disease; PDD, Parkinson’s disease with dementia; PDND,
Parkinson’s disease non-demented; p-tau, phospho-tau; S100B,
S100 calcium binding protein B; t-tau, total-tau.
(DOC)
Table S3 P-values of serum NAb titres and SNPs. For
Single nucleotide polymorphisms (SNPs) the respective gene name
and reference SNP ID number (rs#) are given. NAb titres of
scrambled Abeta1–40 were subtracted from other NAb titres, and
were logarithmized afterwards. P-values of NAb titres were
calculated using the Wilcoxon signed rank test/Chi2 approxima-
tion. Post-hoc analyses were performed for comparison of NAb
titres and single nucleotide polymorphisms between the following
cohorts: PD patients versus controls, Parkinson’s disease non-
demented (PDND) versus Parkinson’s disease with dementia
(PDD). P-values ,0.0025 (0.05/20) were considered significant.
Abeta1–42, Amyloid-beta1–42; Apo E4, Apolipoprotein E4; Asyn,
Alpha-synuclein; GSK3B, Glycogen synthase kinase 3 beta; HLA-DRA,
Human leucocyte antigen/Major histocompatibility complex, class II, DR
alpha chain; HSPA5, Heat shock 70 kDa protein 5; MBP, Myelin basic
protein; MOG, Myelin oligodendrocyte glycoprotein; NAb,
naturally occuring autoantibody; PD, Parkinson’s disease; PDD,
Parkinson’s disease with dementia; PDND, Parkinson’s disease
non-demented; S100B, S100 calcium binding protein B; SNCA,
Synuclein alpha; STK39, Serine threonine kinase 39.
(DOC)
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